ICER’s favourable assessment of Bluebird Bio’s gene therapy Zynteglo may have important pricing and reimbursement implications

Forbes

5 May 2022 - ICER evaluated the clinical and cost-effectiveness - as well as budgetary impact - of one of two gene therapies bluebird bio has submitted to the FDA for approval; Zynteglo (betibeglogene autotemcel), indicated for beta thalassemia. 

ICER’s assessment suggests the product is cost effective. Given the growing influence ICER has on payer decision-making, this could facilitate Zynteglo’s market access.

Read Forbes article

Michael Wonder

Posted by:

Michael Wonder